🇺🇸·18h agoResearch
NCT06100744: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Study type: INTERVENTIONAL. Phase: PHASE3.
Publisher
C
ClinicalTrials.gov
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- ClinicalTrials.gov
- Region
- USA
- Scope
- Research
- Published
- July 31, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Study type: INTERVENTIONAL. Phase: PHASE3.
Source route
Continue on clinicaltrials.gov
Leave the platform to read the original full article on the publisher site.
Source: ClinicalTrials.gov
Scope: Research
Related coverage
More related coverage
CORDIS/9h ago
CORDIS project: LIVEMAP: Live-cell mapping of drug–protein interactions across the human proteome
CORDIS/9h ago
CORDIS project: Short Tandem Repeat Instability QuantIfier for Next-Generation sequencing
CORDIS/9h ago
CORDIS project: Harnessing biobanking, Organ models, and Patient Empowerment for a better quality of life for women living within Polyendocrine Metabolic Ovary Syndrome
CORDIS/9h ago